high mobility group box 3 pseudogene 32Genealiases: []
Q-omics provides the consensus-scored HMGB3P32 profile across patient tissues and cancer cell-line models. HMGB3P32 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HMGB3P32 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HMGB3P32 RNA expression shows 15,762 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where HMGB3P32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P32 survival associations across molecular data types. HMGB3P32 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P32 RNA expression–survival associations across cancer types. High HMGB3P32 expression shows unfavorable associations in KIRP and UVM, but favorable associations in BLCA, SKCM, STAD and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for HMGB3P32 RNA expression.
This table summarizes HMGB3P32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P32 shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, STAD, COAD and LIHC. The KIRC box plot shows higher HMGB3P32 RNA expression in tumor versus normal tissue (log2 FC = +0.402, t-test p < 0.001).
This table shows molecular features associated with HMGB3P32 in patient tissues and cancer cell lines. In patient samples, HMGB3P32 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
